• Rüdiger Hehlmann, David Grimwade, Bengt Simonsson, Jane Apperley, Michele Baccarani, Tiziano Barbui, Giovanni Barosi, Renato Bassan, Marie C Béné, Ute Berger, Thomas Büchner, Alan Burnett, Nicolas C P Cross, Theo J M de Witte, Hartmut Döhner, Hervé Dombret, Hermann Einsele, Georg Engelich, Robin Foà, Christa Fonatsch, Nicola Gökbuget, Elaine Gluckman, Alois Gratwohl, Francois Guilhot, Claudia Haferlach, Thorsten Haferlach, Michael Hallek, Jörg Hasford, Andreas Hochhaus, Dieter Hoelzer, Jean-Jaques Kiladjian, Boris Labar, Per Ljungman, Ulrich Mansmann, Dietger Niederwieser, Gert Ossenkoppele, José M Ribera, Harald Rieder, Hubert Serve, Petra Schrotz-King, Miguel A Sanz, Susanne Saussele, and European LeukemiaNet.
• Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany. r.hehlmann@urz.uni-heidelberg.de
• Haematologica. 2011 Jan 1;96(1):156-62.

AbstractThe only way to cure leukemia is by cooperative research. To optimize research, the European LeukemiaNet integrates 105 national leukemia trial groups and networks, 105 interdisciplinary partner groups and about 1,000 leukemia specialists from 175 institutions. They care for tens of thousands of leukemia patients in 33 countries across Europe. Their ultimate goal is to cure leukemia. Since its inception in 2002, the European LeukemiaNet has steadily expanded and has unified leukemia research across Europe. The European LeukemiaNet grew from two major roots: 1) the German Competence Network on Acute and Chronic Leukemias; and 2) the collaboration of European Investigators on Chronic Myeloid Leukemia. The European LeukemiaNet has improved leukemia research and management across Europe. Its concept has led to funding by the European Commission as a network of excellence. Other sources (European Science Foundation; European LeukemiaNet-Foundation) will take over when the support of the European Commission ends.

11 keywords...

hide…